Oppenheimer raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $30 from $25 and keeps an Outperform rating on the shares. The firm notes MoonLake reported Q3 financials and provided a business update, including results from the Phase 2 LEDA study in palmo-plantar pustulosis, interim adolescent hidradenitis suppurativa data and interim long-term efficacy data from VELA-1/VELA-2.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics price target raised to $8 from $7 at Goldman Sachs
- MoonLake Immunotherapeutics Announces $75M Share Offering
- MoonLake Immunotherapeutics’ SLK Program: Buy Rating Backed by Promising Trial Results and Upcoming Catalysts
- MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating
- MoonLake Immunotherapeutics: Promising Clinical Trials and Strategic Regulatory Advances Boost Confidence in Sonelokimab